Study Evaluating rhIL-11 in Active Crohn's Disease

This study has been completed.

Sponsor:

Information provided by (Responsible Party):

Wyeth is now a wholly owned subsidiary of Pfizer

ClinicalTrials.gov Identifier:

NCT00040521

First received: June 27, 2002

Last updated: February 7, 2013

Last verified: September 2005

History of Changes

Purpose

The purpose of this study is to assess the activity of multiple doses of oral rhIL-11 in patients with active Crohn's disease (Crohn's Disease Activity Index [CDAI] score from 220-400).

Condition	Intervention	Phase
Crohn Disease Inflammatory Bowel Disease	Drug: Recombinant Human Interleukin-11 (rhIL-11)	Phase 2


Study Type:	Interventional
Study Design:	Allocation: Randomized Masking: Double Primary Purpose: Treatment
Official Title:	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Orally Administered Recombinant Human Interleukin-11 (rhIL-11) for the Treatment of Patients With Active Crohn's Disease

Resource links provided by NLM:

Genetics Home Reference related topics: Crohn disease

MedlinePlus related topics: Crohn's Disease

Drug Information available for: Oprelvekin

U.S. FDA Resources

Further study details as provided by Wyeth is now a wholly owned subsidiary of Pfizer:


Study Start Date:	April 2002
Study Completion Date:	October 2003
Primary Completion Date:	October 2003 (Final data collection date for primary outcome measure)

Eligibility


Ages Eligible for Study:	16 Years and older (Child, Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Documented, signed and dated informed consent to participate in this trial prior to any study related procedures being performed.
Men and women age 16 years and over.
Diagnosis of Crohn's disease for at least 6 months that has been appropriately documented and confirmed by radiological studies, endoscopy (with histological examination preferred), or surgical pathology (Patients with a diagnosis of Crohn's disease for less than 6 months may be included if the diagnosis is confirmed by a biopsy characteristic of Crohn's disease)

Exclusion Criteria:

Use of the following medications within the specified time period prior to randomization:

Nonsteroidal anti-inflammatory drugs (NSAIDs; including Cyclooxygenase-2 [COX-2] inhibitors and >500 mg/day acetylsalicylic acid)
Codeine-containing compounds
Corticosteroid enemas

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00040521

Locations


United States, Colorado

Arvada, Colorado, United States, 80002
United States, North Carolina

Chapel Hill, North Carolina, United States, 27599-7032

Sponsors and Collaborators

Wyeth is now a wholly owned subsidiary of Pfizer

Investigators


Study Director:	Medical Monitor	clinicaltrialinfo@wyeth.com

More Information


Responsible Party:	Wyeth is now a wholly owned subsidiary of Pfizer
ClinicalTrials.gov Identifier:	NCT00040521 History of Changes
Other Study ID Numbers:	3067K5-208 B2491021 ( Other Identifier: Pfizer )
Study First Received:	June 27, 2002
Last Updated:	February 7, 2013

Keywords provided by Wyeth is now a wholly owned subsidiary of Pfizer:


Crohn's Disease Active Crohns Disease

Additional relevant MeSH terms:


Crohn Disease Inflammatory Bowel Diseases Gastroenteritis Gastrointestinal Diseases	Digestive System Diseases Intestinal Diseases Oprelvekin Antineoplastic Agents

ClinicalTrials.gov processed this record on September 20, 2017

To Top